Loading...
Market
Major US insurance coverage for Kebilidi by June 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Announcements from major US insurance providers or PTC Therapeutics
Story
FDA Approves PTC Therapeutics' Brain-Delivered Gene Therapy Kebilidi for AADC Deficiency
Nov 14, 2024, 01:23 PM
The U.S. Food and Drug Administration (FDA) has approved PTC Therapeutics' gene therapy for Aromatic L-amino acid decarboxylase (AADC) deficiency, a potentially fatal enzyme deficiency disorder. This therapy, marketed under the name Kebilidi, is the first brain-delivered gene therapy approved in the United States. The approval was granted following an open-label study involving 13 patients and the use of historical control data.
View original story
Similar markets
All major insurers • 25%
Most major insurers • 25%
Some major insurers • 25%
Few or none • 25%
Less than 20 • 33%
20-40 • 33%
More than 40 • 33%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
